Evidence map›Paper›PMID 36471257›Full record

Trial reportBMC cancer2022

Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial.

Yingjie Hu, Yingyan Han, Yuanming Shen, Jing Chen, Yaheng Chen, Yile Chen, Junying Tang, Min Xue, Li Hong, Wenjun Cheng and 26 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03308591 (Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03308591 phase3completednot on this map

Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial

TypeinterventionalSponsorHuazhong University of Science and TechnologyRan2016 to 2022Enrolled774ConditionsUterine Cervical Neoplasm, Cervical Cancer, Uterine Cervical CancerArmsNACT, RT+PLND, Adjuvant chemotherapy
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024
    Review
  11. Article
  12. Article
  13. Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 1 country.

Yingjie Hu *Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yingyan Han *Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yuanming Shen *Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jing ChenDepartment of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yaheng ChenDepartment of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yile ChenDepartment of Gynecologic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Junying TangDepartment of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Min XueDepartment of Gynecology and Obstetrics, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Li HongDepartment of Obstetrics and Gynaecology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Wenjun ChengDepartment of Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Danbo WangDepartment of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Zhiqing LiangDepartment of Obstetrics and Gynecology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Yifeng WangDepartment of Gynecology, Obstetrics and Gynecology Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qinghua ZhangDepartment of Obstetrics and Gynecology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Hui XingDepartment of Obstetrics and Gynaecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Yu ZhangDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cunjian YiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Zhiying YuDepartment of Gynecology, The First Affiliated Hospital of Shenzhen University, Health Science Center; Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
Youguo ChenDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Manhua CuiDepartment of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin, China.
Cailing MaDepartment of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Hongying YangDepartment of Gynecology, Yunnan Tumor Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Ruizhen LiDepartment of Gynecology and Obstetrics, Shenzhen Hospital of Beijing University, Shenzhen, Guangdong, China.
Ping LongThe Second People's Hospital of Jingmen, Hubei, Jingmen, China.
Yu ZhaoDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Pengpeng QuDepartment of Gynecology Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.
Guangshi TaoDepartment of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lihua YangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, Kunming Medical University, Kunming, Yunnan, China.
Sufang WuDepartment of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhihua LiuDepartment of Gynecology, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Ping YangDepartment of Obstetrics and Gynecology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.
Weiguo LvDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xing XieDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Ding MaDepartment of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Hui WangDepartment of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. huit71@sohu.com.
Kezhen LiDepartment of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. tjkeke@126.com.
Tongji Hospital · CNWomen's Hospital, School of Medicine, Zhejiang University · CNCentral South University · CNHuazhong University of Science and Technology · CNKunming Medical University · CNSouthern Medical University · CNCentral Hospital of Wuhan · CNChina Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CNFirst People’s Hospital of Jingmen · CNNanjing Medical University · CNSecond Affiliated Hospital of Jilin University · CNShanghai Jiao Tong University · CNShenzhen University Health Science Center · CNShihezi University · CNSoochow University · CNSouthwest Hospital · CNThird Xiangya Hospital · CNTianjin Central Hospital of Gynecology Obstetrics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative neoadjuvant chemotherapy (NACT) has been widely used in developing countries for the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) stages IB3 and IIA2 cervical cancer. However, the effectiveness of NACT and treatment options for NACT-insensitive patients have been concerning. This study will assess prognostic differences between NACT and primary surgery treatment (PST), determine factors associated with prognosis, and explore better adjuvant treatment modalities for NACT-insensitive patients.

methodsThis study analyzed clinical characteristics, pathological characteristics, treatment options, and follow-up information of 774 patients with FIGO stages IB3 and IIA2 cervical cancer from 28 centers from January 2016 to October 2019 who participated in a multicenter, prospective, randomized controlled trial.

resultsFor patients undergoing NACT, the 5-year OS and PFS rate was 85.8 and 80.5% respectively. They were similar in the PST group. There was no significant difference in OS and PFS between clinical response (CR)/partial response (PR) groups and stable disease (SD)/progressive disease (PD) groups. Apart from deep cervical invasion (p = 0.046) affecting OS for patients undergoing NACT, no other clinical and pathological factors were associated with OS. 97.8% of NACT-insensitive patients opted for surgery. If these patients did not have intermediate- or high-risk factors, whether they had undergone postoperative adjuvant therapy was irrelevant to their prognosis, whereas for patients with intermediate- or high-risk factors, adjuvant chemotherapy resulted in better PFS (chemotherapy vs. no therapy, p < 0.001; chemotherapy vs. radiotherapy, p = 0.019) and OS (chemotherapy vs. no therapy, p < 0.001; chemotherapy vs. radiotherapy, p = 0.002).

conclusionsNACT could be a choice for patients with FIGO stages IB3 and IIA2 cervical cancer. The main risk factor influencing prognosis in the NACT group is deep cervical invasion. After systematic treatment, insensitivity to NACT does not indicate a poorer prognosis. For NACT-insensitive patients, Chinese prefer surgery. Postoperative adjuvant therapy in patients with no intermediate- or high-risk factors does not improve prognosis, and chemotherapy in patients with intermediate- and high-risk factors is more effective than radiation therapy and other treatments.

trial registrationThe study was prospectively registered on ClinicalTrials.gov (NCT03308591); date of registration: 12/10/2017.

Indexed as

Neoadjuvant TherapyUterine Cervical NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansHysterectomyNeoplasm StagingProspective StudiesRetrospective StudiesTreatment OutcomeCervical cancerNeoadjuvant chemotherapyNon-respondersPrognosisRadical surgery

Identifiers

PMID36471257
PMCPMC9724322
OpenAlexW4310776689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.